File:PMC5425965 13023 2017 645 Fig1 HTML.png

License

CC0 1.0 Universal (CC0 1.0) Public Domain Dedication

&

Attribution 4.0 International (CC BY 4.0)

Summary

Author:L. Polivka, J. S. Diana, A. Soria, C. Bodemer, P. Quartier,S. Fraitag, B. Bader-MeunierParis Descartes-Sorbonne Paris Cité University and IMAGINE Institute, Department of Pediatric Hematology-Immunology and Rheumatology, Necker-Enfants Malades Hospital (AP-HP), 149 rue de Sèvres,Sorbonne University, UPMC University Paris 06, Immunology and Infectious diseases Center – Paris (Cimi-Paris), INSERM U1135, Department of Dermatology and Allergology, Tenon Hospital (AP-HP), Department of Dermatology, Necker-Enfants Malades Hospital (AP-HP), Department of Pathology, Necker-Enfants Malades Hospital (AP-HP)(Openi/National Library of Medicine) Source: https://openi.nlm.nih.gov/detailedresult?img=PMC5425965_13023_2017_645_Fig1_HTML&query=Canakinumab&it=xg&req=4&npos=12 Description:Fig1: Clinical and histopathological findings of patients #1 and #2. a Patient #1: urticaria during flares. b Patient #1: widespread exanthema after three injections of canakinumab. c Patient #2: skin rash, seven days after the initiation of anakinra. d, e Patient #1: histologic assessment of the skin biopsy, showing confluent keratinocyte necrosis (d) and moderate perivascular lymphocytic infiltrate (e)